Business Wire

MN-DIGI-INTERNATIONAL

17.1.2023 15:01:48 CET | Business Wire | Press release

Share
Digi International Launches Digi Containers to Improve Development, Operation, and Management of Custom Applications on Digi Cellular Routers

Digi International, (NASDAQ: DGII), a leading global provider of Internet of Things (IoT) solutions, connectivity products, and services, today launched Digi Containers, a software service that enables the development and operation of custom applications on Digi cellular routers that run DAL OS. Digi Containers leverage the Digi Remote Manager® platform as the central portal for deploying and managing these applications.

The Digi Containers service helps developers take the fullest advantage of edge computing by providing the flexibility to deploy new services and apps while consolidating edge-processing hubs. These edge applications offer low latency and near-real-time responsiveness with the agility to respond to evolving use cases.

Through Digi Containers, developers employ Lightweight Linux Containers (LXCs) — essentially virtual machines (VMs) that share the physical device’s running kernel. This enables processes inside a container to run at native speed as if they are actually running directly on the host device. Since containers are lightweight and portable, they offer both security and flexibility. This enables developers to expand on the capabilities of Digi solutions to support specific needs.

As a value-added service for Digi cellular routers, Digi Containers enable users to upload, manage, deploy, and monitor container-based applications through Digi Remote Manager. This empowers companies to orchestrate and manage a complex series of containers in various structures and configurations. Digi Containers provide:

  • Portability – A containerized application can be deployed in private and public clouds. Companies gain flexibility because they can easily move workloads among environments and providers.
  • Scalability – Containers can scale horizontally (i.e., you can “clone” identical containers within the same cluster to expand capacity/throughput as needed). By running only what is needed, when needed, costs decrease significantly.
  • Increased security – By design, containers are inherently isolated. If one container is compromised, others won’t be affected.
  • Speed – Autonomy from the operating system gives greater control. You can start/stop a container in seconds. You achieve faster development and operational speed and a faster and smoother user experience.
  • Efficiency – Since a separate operating system isn’t required, containers require fewer resources than VMs. You can run several containers on a single server. Less hardware means lower costs and fewer points of failure.

“The launch of Digi Containers unlocks the power of edge computing on Digi cellular routers,” said Kinana Hussain, Vice President of Product Management. “By building in the embedded software environment on our devices, along with their inherent computational capabilities, developers can tap into a rich and growing set of features, capabilities, and services. These are all signed, vetted, and distributed as part of the Digi TrustFence® security framework to more easily create and support a variety of demanding containerized applications in the enterprise, industrial, and transportation markets.”

Digi Enhances Network Analytics Application

Recently, Digi also upgraded Digi intelliFlow® in Digi Remote Manager, further strengthening Digi’s edge-to-cloud software stack. Digi intelliFlow provides a graphical visualization of network application data, focusing on the top 10 users or top 10 destinations. This intuitive representation of network activity allows organizations to update settings on Digi routers or tailor the network to the site’s needs. Digi intelliFlow provides recent data and a historical reference to keep networks running smoothly. intelliFlow addresses excessive data usage with custom alarms that alert administrators when data limits are approaching.

“Our long-term vision is to enable a full suite of market vertical-specific value-added services that leverage our robust edge-to-cloud software stack to help our customers maximize their IoT investments while focusing on their core business,” said Hussain.

About Digi International

Digi International (NASDAQ: DGII) is a leading global provider of IoT connectivity products, services, and solutions. It helps companies create next-generation connected products and deploy and manage critical communications infrastructures in demanding environments with high levels of security and reliability. Founded in 1985, Digi has helped customers connect more than 100 million things and counting. For more information, visit www.digi.com.

To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.

View source version on businesswire.com: https://www.businesswire.com/news/home/20230117005154/en/

About Business Wire

Business Wire
Business Wire
101 California Street, 20th Floor
CA 94111 San Francisco

http://businesswire.com
DK

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

Westinghouse Celebrates Record-breaking 80 Years of Nuclear Fuel Manufacture at Springfields30.3.2026 14:00:00 CEST | Press release

Fuel manufactured at Springfields has generated enough energy to supply the UK’s electricity demand for 26 years, avoiding the emission of nearly 3 billion tonnes of CO2 The Westinghouse Springfields facility in Lancashire, UK, has marked a significant milestone as the oldest continuous nuclear fuel manufacturing site in the world, starting from its original license on the 28th, March 1946. The site was chosen by the UK Government to develop nuclear fuel for the world’s earliest civil nuclear power stations, as well as subsequent Magnox and Advanced Gas Reactors (AGR) reactors. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260330135973/en/ From left to right: Sophie Lemaire; Marc Chevrel; Rory O'Neill; Craig Boothby; and Robert Gofton, CEO at Nuclear Institute Across the last eight decades, the Springfields site has supported the UK nuclear fleet, manufacturing more than eight million AGR pins, sintering and pressing over 5

HistoSonics Treats First Patients Evaluating the Edison® Histotripsy System for the Treatment of Benign Prostatic Hyperplasia (BPH)30.3.2026 14:00:00 CEST | Press release

HistoSonics, the developer of the Edison® Histotripsy System and novel histotripsy therapy platform, today announced the successful treatments of the first patients in WOLVERINE, a prospective feasibility trial evaluating the Edison® Histotripsy System for the treatment of benign prostatic hyperplasia (BPH) at Prince of Wales Hospital in Hong Kong, a teaching hospital for The Chinese University of Hong Kong. The Edison System is a novel, non-invasive, image guided platform that uses the mechanical properties of focused ultrasound, called histotripsy, to destroy unwanted tissue without the need for invasive procedures, and with potentially fewer side effects than traditional, invasive therapies. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260330349844/en/ HistoSonics Non-Invasive Edison Histotripsy System. Image credit: HistoSonics WOLVERINE is a prospective, multi-center, single-arm feasibility trial designed to evaluate

Biocytogen Grants Taisho Pharmaceutical a License to its RenNano® Fully Human Heavy Chain-Only Antibody Discovery Platform30.3.2026 13:00:00 CEST | Press release

Biocytogen Pharmaceuticals (Beijing) Co., Ltd. (Biocytogen, SSE: 688796; HKEX: 02315), a global biotechnology company that drives the research and development of novel antibody-based drugs with innovative technologies, today announced that it has entered into a platform license agreement with Taisho Pharmaceutical Co., Ltd. (“Taisho”), granting Taisho the right to access and use Biocytogen’s proprietary RenNano® fully human heavy chain-only antibody (HCAbs) discovery platform for its internal research and development programs. Under the terms of the agreement, Taisho will leverage RenNano® mice to enable the generation and screening of fully human HCAbs in vivo and to support downstream research associated with antibody discovery. Financial terms of the agreement have not been disclosed. “We are very pleased to enter into this collaboration with Taisho,” said Dr. Yuelei Shen, President and CEO of Biocytogen. “RenNano® is a robust and powerful fully human VHH discovery platform that pro

Meiji Seika Pharma Invests in Centivax to Develop Next Generation Universal Vaccine Platform30.3.2026 13:00:00 CEST | Press release

Meiji Seika Pharma Co., Ltd. (Head Office: Chuo-ku, Tokyo, President and Representative Director: Toshiaki Nagasato) today announced a strategic investment in Centivax, Inc. (Head Office: South San Francisco, CA, USA), a biotechnology company developing next-generation vaccines and therapies for universal protection against highly diverse targets. Centivax’s lead program includes a universal seasonal influenza vaccine (Centi-Flu 01) currently in a Phase 1 clinical study. Unlike conventional seasonal flu vaccines, which must be manufactured annually based on recommended candidate vaccine viruses, Centivax’s platform focuses both antibody and cellular immune responses on conserved regions of the influenza virus that cannot mutate and are shared across strains and distant subtypes. This approach aims to generate broad, consistent, and durable immunity against both seasonal and pandemic influenza. Meiji’s strategic investment aims to accelerate the advancement of Centi-Flu 01 and further a

Samsung Biologics Strike: Labor Union Warns of CDMO Supply Chain Risks Following Overwhelming Vote30.3.2026 11:52:00 CEST | Press release

Union members overwhelmingly approve strike action with 95.52% voting in favor on a 95.38% turnout, clearing the final legal hurdle after mediation ceased.Union emphasizes this is a fight against structural corporate governance issues, citing unresolved allegations concerning unfair labor practices and ESG compliance risks.Management adhered to a group-level wage guideline rather than bargaining on the basis of Samsung Biologics' own performance, exposing a lack of independent bargaining authority. The Samsung Biologics Labor Union (President: Jaesung Park), representing approximately 75% of the company's total employees, announced today that its members have overwhelmingly voted in favor of a strike, with 95.52% voting in favor on a 95.38% turnout during a voting period from March 24 to March 29. Following the Incheon Regional Labor Relations Commission's decision to cease mediation, the union has now secured the legal mandate to strike. The union stressed that this strike is not mere

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
World GlobeA line styled icon from Orion Icon Library.HiddenA line styled icon from Orion Icon Library.Eye